Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 7, 2011
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial
William J Sandborn, Stefan Schreiber, Brian G Feagan, et al.
CNS Drugs
|
August 21, 2013
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study
Ralf W Dittmann, Esther Cardo, Peter Nagy, et al.
CNS Drugs
|
June 27, 2013
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents
César Soutullo, Tobias Banaschewski, Michel Lecendreux, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines
|
February 13, 2016
Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study
Jeffrey H Newcorn, Valerie Harpin, Michael Huss, et al.
Cancer
|
March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
The Lancet. Oncology
|
July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology
|
August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine
|
October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
The Lancet. Oncology
|
July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander, Val Gebski, Emma Gibbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 7, 2011
Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial
William J Sandborn, Stefan Schreiber, Brian G Feagan, et al.
CNS Drugs
|
August 21, 2013
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study
Ralf W Dittmann, Esther Cardo, Peter Nagy, et al.
CNS Drugs
|
June 27, 2013
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents
César Soutullo, Tobias Banaschewski, Michel Lecendreux, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines
|
February 13, 2016
Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study
Jeffrey H Newcorn, Valerie Harpin, Michael Huss, et al.
Cancer
|
March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
The Lancet. Oncology
|
July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology
|
August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine
|
October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
The Lancet. Oncology
|
July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander, Val Gebski, Emma Gibbs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Page
of 2